Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
aborted, aggressive, Antidilutive, arbitrage, bar, baseline, biometric, Biopharma, bore, borrowed, borrowing, bribed, Bribery, bribing, build, Carlo, carryover, cellular, CFO, cohort, condensed, confusion, Corrupt, corruption, counterparty, currency, depth, destruction, dissemination, embedded, endpoint, FCPA, feedback, GDPR, genetic, great, ID, implicit, improperly, ineffective, intrinsic, iXBEL, laundering, lien, lodge, Monte, mRNA, NaN, NJ, occupy, Omicron, presence, problem, processing, prolonged, qualitative, quantitative, reclassed, safeguarding, sample, SCA, score, sensitive, Shortfall, simulation, spike, sublingual, supervisory, topline, unsatisfactory, vaccine, variant, virtually, vitro, Wafermine, weather, whichever
Filing tables
Filing exhibits
- 10-K Annual report
- 4.21 Description of Securities of Seelos Therapeutics, Inc.
- 4.22 Amendment to Convertible Promissory Note
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
SEEL similar filings
Filing view
External links
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Raj Mehra, Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Seelos Therapeutics, Inc. on Form 10-K for the year ended December 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Seelos Therapeutics, Inc.
Date: March 4, 2022 | By: | /s/ Raj Mehra, Ph.D. |
Name: | Raj Mehra, Ph.D. | |
Title: | Chief Executive Officer and President |